10:17 AM EDT, 04/29/2024 (MT Newswires) -- Laboratory Corp of America Holdings ( LH ) , or Labcorp, said Monday that the US Food and Drug Administration has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic device to determine patient eligibility for treatment with Pfizer's ( PFE ) Beqvez.

Beqvez is a recently FDA-approved gene therapy for hemophilia B, a genetic bleeding disorder.

Price: 199.87, Change: +1.47, Percent Change: +0.74